PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of elifeeLifeRecent contentAbout eLifeFor authorsSign up for alerts
 
eLife. 2017; 6: e27711.
PMCID: PMC5542768

Structural insight into the activation of a class B G-protein-coupled receptor by peptide hormones in live human cells

Yibing Shan, Reviewing editor
Yibing Shan, DE Shaw Research, United States;

Abstract

The activation mechanism of class B G-protein-coupled receptors (GPCRs) remains largely unknown. To characterize conformational changes induced by peptide hormones, we investigated interactions of the class B corticotropin-releasing factor receptor type 1 (CRF1R) with two peptide agonists and three peptide antagonists obtained by N-truncation of the agonists. Surface mapping with genetically encoded photo-crosslinkers and pair-wise crosslinking revealed distinct footprints of agonists and antagonists on the transmembrane domain (TMD) of CRF1R and identified numerous ligand-receptor contact sites, directly from the intact receptor in live human cells. The data enabled generating atomistic models of CRF- and CRF(12-41)-bound CRF1R, further explored by molecular dynamics simulations. We show that bound agonist and antagonist adopt different folds and stabilize distinct TMD conformations, which involves bending of helices VI and VII around flexible glycine hinges. Conservation of these glycine hinges among all class B GPCRs suggests their general role in activation of these receptors.

DOI: http://dx.doi.org/10.7554/eLife.27711.001

Research Organism: Human

Introduction

G-protein-coupled receptors (GPCRs) of class B comprise a family of 15 transmembrane receptors that respond to endocrine factors and regulate vital functions in mammals, including glucose and calcium homeostasis, pain transmission and gastrointestinal regulation (Bortolato et al., 2014; Wootten et al., 2017; Culhane et al., 2015; Pal et al., 2012). While a number of clinical drugs already employ class B GPCRs to treat hypercalcemia, osteoporosis, diabetes and eating disorders, many new therapies targeting these receptors are being pursued (Bortolato et al., 2014; Wootten et al., 2017). In addition to the heptahelical architecture of the transmembrane domain (TMD) common to all GPCRs, class B receptors are defined by a large, glycosylated N-terminal extracellular domain (ECD, ~120–160 residues in length) (Culhane et al., 2015; Pal et al., 2012). The native ligands of class B GPCRs are long peptide hormones, which bear distinct functional sites at the two termini (Pal et al., 2012; Beyermann et al., 2000). The C-terminal portion of the peptide forms selective high-affinity interactions with the ECD and drives selective receptor binding, while the N-terminal segment interacts with the TMD and triggers receptor activation (two-domain binding model) (Culhane et al., 2015; Pal et al., 2012; Dong et al., 2014; Beyermann et al., 2000).

While recent structural studies have provided major insights into activation of class A GPCRs by small molecule ligands, little is known about activation mechanisms of class B GPCRs by peptide hormones, despite availability of some structural information for these receptors. Thus, crystal structures have revealed the binding mode of ligand C-termini to the isolated ECDs of several class B receptors, but they excluded TMDs (Bortolato et al., 2014; Pal et al., 2012). TMD structures for the glucagon receptor and the corticotropin-releasing factor (CRF) receptor type 1 (CRF1R) were also solved, but they lack the ECDs and represent the receptors in an inactive state bound to allosteric small molecule inhibitors (Hollenstein et al., 2013; Jazayeri et al., 2016; Siu et al., 2013). Most recently, the full-length crystal structure of the glucagon receptor in complex with a small molecule acting as negative allosteric modulator (Zhang et al., 2017) and the cryo-electron microscopy (cryo-EM) structure of the calcitonin receptor in complex with a Gs-protein heterotrimer were also solved (Liang et al., 2017). While the complex used for cryo-EM included a peptide agonist and the ECD, high flexibility prevented structure determination in this part of the complex, thus highlighting the limitations of structural approaches that require conformational rigidity in the protein, and leaving interaction modes of peptide agonists and antagonists with full-length class B GPCRs unresolved.

It is a general feature of class B natural agonists that they turn into partial agonists and then into antagonists by successively truncating residues at the N-terminus. However, the molecular basis of this phenomenon has never been investigated. We reasoned that comparing the binding mode of class B agonists and orthosteric N-truncated antagonists would shed light on conformational changes in the receptor TMD that lead to activation and may facilitate drug discovery at these receptors.

As prototype class B receptor, we used the CRF1R, which is a key regulator in stress response by triggering the release of adrenocorticotropic hormone (ACTH) in the pituitary gland (Bale and Vale, 2004; Stengel and Taché, 2014). Small molecule and peptide-based clinically applicable antagonists of CRF1R have long been sought after for treating stress-related disorders such as anxiety and depression (Liapakis et al., 2011; Grigoriadis and Hoare, 2017). In humans, CRF1R is activated by the two 41- and 40-mer endogenous peptide agonists CRF and Urocortin I (Ucn1). N-terminal truncation of the first eight residues of CRF yields antagonists retaining some weak partial activity, such as CRF(9-41) (Rivier et al., 1984; Rivier and Rivier, 2014). Signaling is completely lost by truncating 11 residues, as in [DPhe12, Nle21,38]-CRF(12-41) and Astressin (Gulyas et al., 1995). Although we have recently revealed the binding mode of the agonist Ucn1 on the CRF1R (Coin et al., 2013, 2011), receptor interactions with peptide antagonists remain enigmatic.

In this study, we characterized the CRF1R complexes with the agonist CRF and three N-truncated peptide antagonists. We used unnatural amino acid photo-crosslinking and pair-wise chemical crosslinking to reveal ligand-receptor interactions in live cells. We defined ligand footprints on the CRF1R and derived sets of intermolecular contacts, which were applied in extensive conformational sampling to generate molecular models of agonist- and antagonist-bound CRF1R. We found that CRF1R peptide antagonists stabilize different conformations of the CRF1R TMD in respect to the agonists, including large-scale movements of transmembrane helices and changes in the shape of the binding pocket.

Results

Footprints of agonists and antagonists on CRF1R

In first place, we mapped agonist and antagonist footprints on CRF1R in intact 293T cells using the photo-crosslinking amino acid p-azido-Phe (Azi) as a proximity probe.

We compared the binding paths of five peptide ligands: the natural agonists CRF and Ucn1, the two 33-mer antagonists CRF(9-41) and Ucn1(8-40), and the 30-mer antagonist [DPhe12,Nle21,38]-CRF(12-41) (Figure 1A), which from now on we will refer to as dFXCRF(12-41). Activity of all peptides was assessed via cAMP accumulation assays and showed good agreement with literature data (Table 1 and Figure 1B). All truncated peptides right shifted the dose-response curve of their parent agonist and behaved as competitive antagonists (Figure 1C–D).

Figure 1.
Photo-crosslinking mapping of CRF1R to determine footprints of agonists and antagonists.
Table 1.
Properties of synthesized [Lys(ClAc)]-peptide derivatives. X represents substitution of the two Met residues in position 21 and 38 to Norleucine. dF indicates the N-terminal D-Phe12 of the CRF(12-41) analogues. EC50 values of agonists were derived from ...

Azi was incorporated into CRF1R in response to an amber stop codon using a dedicated amino-acyl tRNA synthetase/tRNACUA pair (Coin et al., 2013). The receptor was equipped with a FLAG-tag at the C-terminus. We systematically mapped 119 positions spanning the whole juxtamembrane region of CRF1R, with the sole exclusion of eight known non-tolerant sites (Coin et al., 2013). Cell-surface expression of a representative subset of Azi-CRF1R mutants was determined using both immunoblotting of the C-terminal FLAG and a whole-cell ELISA detecting an ad hoc introduced N-terminal HA epitope (Figure 1—figure supplement 1). We observed a good correlation between the amount of mature glycosylated receptors detected in Western blot and the ELISA signals obtained through detection of the extracellular tag. All mutants showed expression levels in the same order of magnitude, with variations of 0.3–0.9-fold with respect to the wild-type receptor.

Cells expressing each mutant receptor were treated with each of the five ligands and crosslinking was triggered with UV light. If the bound ligand lies within the radius of reach of Azi (~9 Å from Cβ, see also modeling section below), it can be captured by the photo-active moiety (Coin et al., 2013). A covalent ligand-receptor complex is formed, which is detected in Western blot at the approximate molecular weight of the receptor with an anti-ligand antibody. Occurrence of crosslinking was detected at numerous positions distributed along the whole TMD with all ligands (Figure 1E). Residue positions are indicated with Wootten numbering (Wootten et al., 2013) for class B GPCRs, as implemented in GPCRdb (Isberg et al., 2015).

Overall, we observed two different patterns of crosslinking footprints: one shared by the two agonists and a different one for the three antagonists (Figure 2, Figure 2—figure supplement 1). The hits obtained with the agonist CRF overlapped with those of the agonist Ucn1. Likewise, the crosslinking hits of the 33-mer antagonists CRF(9-41) and Ucn1(8-40) were almost identical to each other. The shorter antagonist dFXCRF(12-41) shared the pattern of the 33-mer antagonists with the exception of helix V, where it lacked any hits. Agonist and antagonist footprints differed for hits in ECL2, helix V and VI, whereas all ligands gave a similar pattern in the hinge region, helix I, II, III, VII and ECL3. In ECL2, agonists gave a distinct cluster of three hits (K262ECL2, P264ECL2, G265ECL2) versus the four successive hits found for the antagonists (F260ECL2, G261ECL2, K262ECL2, R263ECL2). In helix V, the 33-mer antagonists featured intense hits (Y2725.39, Q2735.40 and I2775.44) one helix turn deeper than the mapped agonist hits. Similarly, hits I3256.51 and T3266.52 in helix VI were visible only for the longer antagonists and are located one helix turn below the prominent hits L3296.55 and F3306.56 found with all ligands. Notably, three hits at the tip of helix V (D2695.36, Y2705.37 and Y267ECL2, the latter two pointing out of the TMD in the 3D structure) (Hollenstein et al., 2013) were accessible for the two agonists, but were missing for all three antagonists.

Figure 2.
Footprints of peptide agonists and antagonists on CRF1R.

Pair-wise chemical crosslinking

We then focused on deciphering further details of the natural agonist CRF and the full antagonist dFXCRF(12-41) binding to CRF1R via pair-wise chemical crosslinking. We pinpointed intermolecular pairs of proximal ligand-receptor residues using the reaction between Cysteine (Cys) thiols incorporated into the CRF1R and mildly electrophilic α-chloroacetamide (ClAc) moieties incorporated into the peptide (Figure 3A), which occurs only when the two groups are proximal to each other in the associated complex (Coin et al., 2013; Xiang et al., 2013, 2014). Compared to classic disulphide trapping (Dong et al., 2016; Monaghan et al., 2008), this strategy bypasses issues with self-dimerization of Cys-ligands and allows SDS-PAGE analysis under reducing conditions.

Figure 3.
Cys-ClAc pair-wise crosslinking to pinpoint intermolecular pairs of proximal amino acids in ligand-CRF1R complexes.

Cys residues were introduced into CRF1R sites corresponding to the 30 strongest hits of Azi crosslinking including both agonist and antagonist hits. In addition, seven positions in the ECD were rationally selected based on the 3D structures of the ligand-bound CRF1R ECD (Grace et al., 2010; Pioszak et al., 2008). Out of the 37 designed Cys-CRF1R mutants, 35 were expressed on the cell surface and retained the ability to bind CRF1R ligands, as demonstrated by photo-labeling with the Bpa12-Ucn1 ligand (Kraetke et al., 2005; Coin et al., 2013) (Figure 3—figure supplement 1A).

The ClAc moieties were installed into both CRF and dFXCRF(12-41), either as Lysine derivatives [Lys(ClAc)] or directly attached to the N-terminal α-amino group [ClAc0], for a total of nine ClAc-bearing analogues for each ligand (Table 1). Substituted positions cover all residues between V18, which is the putative entrance point of the ligands into the TMD pocket based on homology with our previous model (Coin et al., 2013), and position dF12, which is the N-terminal residue of the antagonist. In addition, Lys(ClAc) was introduced at positions A31 and S33 in the mid region of the peptides, which are expected to interact with the hinge region and ECD of CRF1R. As demonstrated by cAMP accumulation assays, all agonists tolerated the introduced substitutions except for [Lys(ClAc)12]-CRF, which was excluded from further experiments (Table 1). The Lys(ClAc) substitutions were well tolerated also by the antagonists, which behaved essentially like dFXCRF(12-41) both in the cAMP accumulation assay and in photo-crosslinking experiments with Azi-CRF1R mutants (Table 1 and Figure 3—figure supplement 1B).

Chemical crosslinking experiments between ClAc-ligands and Cys-receptors were performed in two blocks for a total of 373 combinations. Based on the two-domain binding model, ligands carrying the ClAc moiety toward the C-terminus were combined with CRF1R mutants bearing Cys in the ECD, whereas ligands substituted in the N-terminal domain were combined with the Cys-CRF1R set substituted in the TMD. Occurrence of pair-wise crosslinking was examined via immunoblotting using an anti-CRF antibody, as described above for the Azi photo-crosslinking experiments. We obtained distinct bands for a subset (5%) of ligand-receptor combinations (Figure 3B). The C-terminus of the agonist and the antagonist gave identical pair-wise hits with the CRF1R ECD (A31-E104ECD and S33-Y73ECD). Likewise, both peptides featured the pair-wise hit V18-V1201.40. However, from E17 on toward the N-terminus, the two-dimensional crosslinking fingerprints of agonist and antagonist differ, showing different interaction sets with the receptor.

Overall, pair-wise crosslinking experiments revealed 7 proximal pairs of ligand-receptor amino acids for the CRF-CRF1R complex and 15 pairs for the dFXCRF(12-41)-CRF1R complex (Table 2). Based on the geometry of the Lys(ClAc) moiety, we estimate that the Cβ-Cβ distance for the reaction between Lys(ClAc) and Cys to take place should not exceed 10 Å. For hits obtained with [ClAc0]-dFXCRF(12-41), which bears the ClAc moiety on the N-terminus, we estimate a maximal distance of 5 Å between the Nα of the peptide and the Cβ of the receptor residue (Figure 4A). This geometrical estimation is further supported by Monte Carlo sampling experiments (Figure 4B).

Figure 4.
Atom-atom distances of residue pairs in the peptide-CRF1R complexes.
Table 2.
Cβ-Cβ and N-Cβ interresidue distance restraints, measured in the molecular models of the CRF- and dFXCRF(12-41)-CRF1R complexes.

3D models for agonist- and antagonist-bound CRF1R

Spatial constraints derived from pair-wise crosslinking were applied as soft harmonic distance restraints in energy-based conformational sampling to obtain 3D atomistic models of agonist- and antagonist-bound CRF1R. CRF and dFXCRF(12-41) were initially docked into a flexible model of full-length rat CRF1R. The model represents the conformation of Ucn1-bound CRF1R from our previous study (Coin et al., 2013) and was derived from the combination of crystal structures of human CRF1R ECD (PDB: 3EHU) (Pioszak et al., 2008) and of the thermostabilized human CRF1R TMD (PDB: 4K5Y) (Hollenstein et al., 2013).

Extensive sampling of peptide and receptor conformations converged to optimized models for the CRF-CRF1R and the dFXCRF(12-41)-CRF1R complexes (Figure 5) where all 7 or 15 experimentally derived pair-wise restraints, respectively, were satisfied (Table 2). Both models are further validated by Azi-crosslinking hits, which have not been used as restraints in the simulations (Figure 5—figure supplement 1). All 56 photo-crosslinking hits, with the only exception of E336ECL3 in the highly flexible ECL3 (see 'Molecular dynamics' section below), were found within the estimated effective radius of Azi crosslinking, with distances between the Cβ of the crosslinking residues and the nearest non-hydrogen atom of the ligand not exceeding 9 Å (Figure 4C) (Coin et al., 2013).

Figure 5.
Comparison of the agonist-bound model CRF-CRF1R with the antagonist-bound model dFXCRF(12-41)-CRF1R.

Agonist-bound CRF1R model

Docked CRF forms a long α-helical segment from the C-terminus to residue V18 (Figure 5). The C-terminal segment (I41-V18) binds to the CRF1R ECD similarly to the crystal structure of CRF1R ECD bound to CRF(26-41) (PDB: 3EHU) (Pioszak et al., 2008), and approaches the TMD antiparallel to the helical stalk of helix I. As CRF enters the TMD in the groove formed by the helices I, II and VII, experimental constraints L15-Q1732.68, H13-F3306.56 and H13-F3447.38 impose disruption of the α-helical conformation and the formation of a short loop in the segment R16-L14. Following this loop, docked CRF shows a second α-helical segment (H13-S7) that lies across the TMD interface. The ligand reaches six of the seven TM helices as deep as Y1241.44, W1692.64, H1993.40, Q2735.40, L3296.55 and S3497.43 (Figure 1—figure supplement 1). No interactions are predicted by the model with helix IV, in accord with the absence of any experimental crosslinking in this helix. Finally, the very N-terminus of CRF (I6-S1) exits the binding pocket through a gap between helix V and VI and extends beyond the TMD.

Overall, the conformation of the docked CRF agonist is similar to the conformation adopted by Ucn1 in the Ucn1-CRF1R model in our previous study (Coin et al., 2013), even though the two models are based on distinct and independent sets of experimental constraints. Notably, the Ucn1 model predicted the kink in the α-helical fold of the agonist at the entrance of the TMD pocket even without pair-wise crosslinks in this region, while new experimental constraints further enforce this conformation in CRF (Figure 5—figure supplement 2).

Both agonist models predict a modest 3.1 Å inward shift of the extracellular tip of helix VII and a movement of ECL3, which compacts the orthosteric binding pocket around the peptide with respect to the wide-open conformation observed in the crystal structure of the CRF1R TMD bound to the small molecule antagonist CP-376395 (PDB: 4K5Y) (Hollenstein et al., 2013). This compaction results from receptor flexibility at the ‘backbone hinges’ Q3557.49 and G3567.50 and at ECL3, leads to an overall gain in the conformational energy of the complex and helps to satisfy the pair-wise distance restraints. Importantly, the TMD model of the CRF-CRF1R complex, based only on restraints identified in this study, satisfies the Ucn1 restraints in the Ucn1-CRF1R model and vice versa, so that the two models strongly validate each other (Table 3). The only substantial difference between CRF and Ucn1-bound CRF1R models is found in the ECD domain, which is now rotated and shifted about 5 Å. This adjustment in the ECD position was induced by the newly derived pair-wise constraints in the C-terminal segment of the peptide, which were missing in the Unc1-CRF1R model, and helped to optimize the key interactions of CRF with the hinge region and ECD pocket.

Table 3.
(A) Cβ-Cβ Interresidue distance restraints experimentally derived for the CRF-CRF1R complex, measured in the model of the CRF-CRF1R complex, and measured at homologous positions in the model of the Ucn1-CRF1R complex. (B) Cβ-Cβ ...

Antagonist-bound CRF1R model

Docked dFXCRF(12-41) antagonist shows both similarities and major differences compared to the conformation of CRF agonist (Figure 5). The C-terminal segments (I41-V18) of both agonist and antagonist similarly interact with CRF1R ECD, the hinge region and the helical stalk of helix I, which accounts for identical patterns of pair-wise restraints and Azi-footprints in these regions (Figures 13, Figure 5—figure supplement 1). However, at the entrance of the binding pocket, where residue E17 of CRF gave chemical crosslinking only with helix VII, the E17 of dFXCRF(12-41) crosslinked to helix VII (I3457.39), helix I (N1231.43), and helix II (Q1732.68). Accordingly, the restrained docking placed E17 about equidistant from the three helices, with the side chain pointing toward the bottom of the TMD. As a consequence, while the C-terminal segment of CRF agonist kept the α-helical conformation up to E17 inclusively, the α-helix in the dFXCRF(12-41) antagonist already unravelled at residue E17. This conformational change is further supported by an additional weak signal of E17-V1762.71 pair-wise crosslinking visible for the antagonist (Figure 3), which was not considered for modeling, but satisfies the 10 Å Cβ-Cβ distance in the model. From E17, docked dFXCRF(12-41) keeps the non-helical conformation all the way up to its N-terminal residue (dF12), which accounts for the series of antagonist-specific pair-wise crosslinking in this region, including crosslinking of L15 with R3417.35 and I3457.39, crosslinking of L14 with N1231.43 and crosslinking of H13 with L3296.55, F3306.56 and F3447.38. Finally, while the N-terminal segment of the CRF agonist is solvent exposed outside the pocket, the N-terminus (dF12) of the dFXCRF(12-41) antagonist is buried inside the TMD, which is corroborated by chemical crosslinking of dF12 with L3296.55, F3306.56 and N3487.42 (Figure 3).

Compared to both the CRF1R crystal structure and the agonist-bound complexes, the predicted conformation of the TMD orthosteric pocket in the dFXCRF(12-41)-CRF1R model is much more compact (Figure 6). Backbone flexibility at the ‘backbone hinges’ Q3557.49 and G3567.50 and extensive conformational sampling of the TMD helical bundle in the modeling procedure led to a dramatic inward shift of the extracellular tips of helices VI and VII by ~6 Å and ~9 Å, respectively, as compared to the conformation of the small-molecule bound TMD crystal (PDB: 4K5Y) (Hollenstein et al., 2013) (Figure 6A, red arrows indicate the inward shift) . This shift of the helices was also accompanied by a shift in the ECL3, which formed a ‘lid’ on top of the N-terminal segment of the bound antagonist. As a control, we attempted docking of the dFXCRF(12-41) peptide in the rigid TMD model that maintains a ‘wide’ conformation of the receptor as in the CRF-CRF1R agonist model. In this case, interactions of the linear N-terminal segment (E17-dF12) of the antagonist in the wide pocket were less energetically favourable. Moreover, the wide conformation of the pocket and the extended linear folding of the antagonist would preclude formation of Azi photo-crosslinking on both helix VI-VII and helix III at the opposite sides of the pocket, which were observed experimentally (Figure 1E). Therefore, conformational changes of the TMD predicted in the flexible dFXCRF(12-41)-CRF1R model are critical for explaining the Azi photo-crosslinking results, which were employed to validate the model. Overall, our models predict two distinct conformations for the TMD of CRF1R when bound to either agonist or antagonist, which we define as ‘wide’ and ‘compact’, respectively (Figure 6).

Figure 6.
Conformational changes within the receptor between the agonist- and antagonist bound complexes.

Molecular dynamics

In order to investigate stability and flexibility of the agonist- and antagonist-bound models, we performed molecular dynamics (MD) simulations of the lipid-embedded peptide-receptor complexes for a period of 1 µs with or without applying the distance restraints derived from pair-wise crosslinking.

The CRF1R complex with CRF agonist maintained integrity in all restrained and unrestrained runs, with all seven amino acid pairs involved in chemical crosslinking retaining a close proximity throughout the simulation (Figure 7A). In unrestrained runs, some residue pairs (e.g. H13-F3447.38) dynamically fluctuated in and out of the range of 10 Å, which is compatible with the crosslinking reaction.

Figure 7.
Interresidue distances during MD simulations.

In these initial runs for the agonist-bound complex, we did not observe dramatic conformational rearrangements of helices in the intracellular part of the CRF1R, as a part of the known GPCR activation mechanism (Rasmussen et al., 2011; Katritch et al., 2014). Indeed, intracellular changes are usually softly coupled with extracellular changes and transitions may require much longer time scales than the 1 μs MD simulations here (Nygaard et al., 2013). To glean intracellular changes accompanying the activation of CRF1R, we therefore used the recent cryo-EM structure of the class B calcitonin receptor in complex with Gs-protein heterotrimer (PDB: 5UZ7) (Liang et al., 2017). To model the conformational change in CRF1R, we applied an outward shift of helix VI to the CRF-CRF1R model, as observed in the calcitonin receptor structure, and submitted it for the MD simulations. This conformation of the complex maintained integrity and ligand contacts in both restrained and unrestrained 1 μs runs, while also maintaining the outward position of helix VI as an indicator of active-like state (Figure 8).

Figure 8.
MD simulations of the modified CRF-CRF1R complex model with active-like conformation of the intracellular TMD region.

The CRF1R complex with dFXCRF(12-41) antagonist also maintained overall integrity in both restrained and unrestrained simulations (Figure 7B,C), with most of the 15 distances determined with pair-wise crosslinking being retained within 10–12 Å. In some unrestrained runs, we observed up to 14 Å deviations in distances H13-F3447.38 and L14-N1231.43, and in contacts of dF12 with L3296.55, F3306.56 and N3487.42. Thus, simulations showed higher flexibility for the linear N-terminal segment of the antagonist in respect to the homologous α-helical segment of the agonist. As a control, we also conducted a series of MD simulations of the antagonist-bound CRF1R starting with the TMD in the agonist-bound ‘wide’ conformation. In this case, the receptor contacts with dFXCRF(12-41) were maintained in the ECD, but most pair-wise crosslinking distances quickly drifted far beyond 14 Å in the TMD, where most interactions with the antagonist N-terminus were completely lost. Therefore, MD showed that the ‘wide’ TMD conformation is less optimal than the ‘compact’ conformation for CRF1R interactions with the dFXCRF(12-41) antagonist (Figure 7—figure supplement 1).

Interestingly, while preserving inter-residue contacts, both the agonist- and the antagonist-bound models showed overall flexibility throughout the simulations. Especially variable was the orientation of the ECD relative to the TMD, which swayed as much as 15–20 Å relative to the membrane normal (Figure 9A,B). High flexibility in MD simulations was also observed for ECL3. Residue E336ECL3, located about 14 Å away from the ligand in the CRF-CRF1R model, came as close as ~6 Å to the peptide during 800 ns simulation runs, thus explaining occurrence of Azi photo-crosslinking at this position (Figure 1, Figure 9C). High flexibility of ECL3 is also supported by the crystal structure of the CRF1R TMD, where only one of the three molecules composing the crystallographic unit shows well defined electron density for ECL3 (Hollenstein et al., 2013).

Figure 9.
Conformational flexibility of ECD and ECL3 during MD simulations.

Discussion

It has been largely believed that N-truncated peptide ligands of class B GPCRs behave as antagonists because they occupy the binding site in the ECD, but are too short to reach the TMD, where activation takes place (Cordomi et al., 2017). Our crosslinking results provide direct evidence that N-truncated antagonists of CRF1R extensively penetrate the TMD, which explains previous observations obtained with chimeric constructs and isolated receptor domains (Hoare et al., 2004, 2005), as well as the fact that the 30-mer antagonist Astressin induces CRF1R internalization (Perry et al., 2005).

Compared to the natural agonists CRF and Ucn1, however, CRF1R antagonists give a different footprint on the receptor TMD, revealing distinct interactions with helix V, helix VI and with ECL2. While agonists protrude into a groove between helices V and VI, the 33-mer peptides, which behave as weak partial agonists at high concentration, do reach both helices (Azi-hits Y2725.39, Q2735.40, I2775.44, I3256.51) but do not penetrate through them (lack of crosslinking at Y267ECL2, D2695.36, Y2705.37). The 30-mer antagonist dFXCRF(12-41), which is not able to activate the receptor at all, shows no contact with helix V, although it maintains contacts with other helices. Taken together, these findings support our previous hypothesis that only agonists can push apart helices V and VI, which constitutes a part of the activation mechanism (Coin et al., 2013). Distinct agonist and antagonist footprints suggest also a role for ECL2 in CRF1R activation. Indeed, ECL2 is known for contributing to ligand binding in CRF1R (Assil-Kishawi and Abou-Samra, 2002; Gkountelias et al., 2009), and a number of studies suggested a role of ECL2 in activation of class B GPCRs (Koole et al., 2012) and other GPCRs (reviewed in [Wheatley et al., 2012]).

Comparison of the atomistic models of CRF1R bound either to CRF or dFXCRF(12-41) shows a different folding for the agonist and the antagonist in the CRF1R TMD, as well as different conformations of the receptor. Following a common C-terminal helical segment interacting with the CRF1R ECD and hinge region, both agonist and antagonist bend at the entrance of the TMD and place the N-terminal segment across the pocket almost parallel to the membrane plane. However, while CRF resumes the helical folding from H13 on, the N-terminus of dFXCRF(12-41) keeps an extended conformation. This conformational difference is clearly required to satisfy the distinct patterns of pair-wise crosslinks in the E17-F12 region of the peptides. The linear N-terminus of the antagonist shows higher flexibility in MD simulations as compared to the corresponding α-helical region of agonist, which suggests weaker and less defined interactions with the receptor and explains the ~10 fold lower binding affinity of CRF1R to dFXCRF(12-41) than to CRF (Gulyas et al., 1995).

To account for the different conformations of the ligands, the energy-optimized models predict a major inward shift of the extracellular halves of helices VI and VII, which is independently validated by a set of photo-crosslinks (Figure 1E, Figure 5—figure supplement 1). Thus, CRF1R TMD compacts around the unstructured N-terminal segment of the antagonist, while it adopts a more open conformation to accommodate the bulkier α-helical segment (S7-H13) and the N-terminal tip (S1-I6) of the agonist, which protrudes between helices V and VI beyond the pocket (Figure 6B). Apparently, stabilization of such a wide open TMD conformation is important for the activation of CRF1R by peptide agonists. Interestingly, the crystal structure of CRF1R TMD bound to the allosteric antagonist CP-376395 (PDB: 4K5Y) (Hollenstein et al., 2013) features an even more open V-shape. However, CP-376395 sits deep in the TMD closer to the G-protein-binding site and likely blocks the signal transmission via a mechanism that is distinct from the action of orthosteric peptide antagonists (Hollenstein et al., 2014).

Movements of the extracellular parts of helices VI and VII rely on Glycine hinges G3246.50 and G3567.50, which are fully conserved among class B GPCRs. Therefore, hinge flexibility in the apo state and stabilization of a specific conformation of these helices upon agonist binding (Figure 6) can be relevant also for the activation mechanism of other class B receptors. Specific details can differ for class B ligands that are shorter than CRF, such as glucagon (Siu et al., 2013; Yang et al., 2015), secretin (Dong et al., 2016) and GLP-1 (Miller et al., 2011; Kirkpatrick et al., 2012), which are thought to penetrate the TMD perpendicularly to the membrane plane. This mechanism may be even more distinct from class A GPCRs, where smaller ligands usually bring only minor changes in the orthosteric pocket, but still result in dramatic rearrangements of the receptor helices VI and VII on the intracellular side, opening the G-protein-binding pocket (DeVree et al., 2016; Rasmussen et al., 2011; Katritch et al., 2014).

The extracellular motions of helices VI and VII in our models for binding of a class B agonist are likely converted into intracellular motions of these helices, corroborating the notion that a global displacement of helices VI and VII is a key feature of GPCR activation in general. While our crosslinking approach reveals details of conformational changes in the ligand-binding pocket of a class B GPCR, the recently solved cryo-EM structure of the calcitonin receptor in complex with the Gs-protein heterotrimer (PDB: 5UZ7) (Liang et al., 2017) provides the first structural evidence for the conformational changes occurring in the intracellular part of a class B helical bundle. Specifically, it confirms that class B GPCR activation, similar to class A (Katritch et al., 2014), involves a large-scale movement of helix VI, which shapes the site for G-protein binding and activation. Note, that according to our active-like CRF-CRF1R model, this helical rearrangement involves a sharp kink around the conserved G6.50 flexible hinge in helix VI, resulting in the outward movement of both extracellular and intracellular tips of helix VI. The stability of this active-like conformation of the CRF-CRF1R complex observed in MD simulations suggests that such dramatic rearrangements can be relevant for the activation mechanism of CRF1R, and potentially of other class B GPCRs.

In summary, we implemented here a hybrid approach combining comprehensive experimental crosslinking with conformational modeling to systematically investigate the mechanism of orthosteric antagonism at a class B GPCR. We show that CRF1R peptide antagonists extensively interact with the receptor TMD, but stabilize a different conformational state in respect to the agonists. Notably, all our experimental data are obtained from the intact full-length, fully glycosylated receptor at the membrane of the live cell, and do not require a rigid conformation of the complex to determine the ligand-receptor interactions. Thus, our results provide key insights into the mechanism of GPCR activation by peptide ligands directly from a native cellular context.

Materials and methods

Materials

Cell lines HEK293 (Cat# ACC-305, RRID:CVCL_0045) and 293T (Cat# ACC-635, RRID:CVCL_0063) were purchased from the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ). Regular testing for mycoplasma contamination is performed using the MycoAlert kit from Lonza. Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), trypsin and penicillin–streptomycin were purchased from Gibco (Life Technologies). DNA restriction enzymes, Phusion DNA polymerase, T4 DNA ligase and PNGase F were from New England Biolabs. Plasmid preparation kits were from Macherey-Nagel. Azi was purchased from Bachem. Protease inhibitor cOmplete EDTA-free from Roche and was used supplemented with 1 mM EDTA. Polyethylenimine MAX was from Polyscience, dissolved in H2O as 10 mg/mL stock solution, aliquoted and stored at −20°C. 9-Fluorenylmethoxycarbonyl (Fmoc)-protected amino acids and resin were purchased from Novabiochem or Iris Biotech. Chloroacetic acid (ClAcOH) was from Sigma.

Peptide synthesis

Peptides were synthesized on a Syro I robot synthesizer (MultiSyntech) using a standard Fmoc/tert-butyl protocol (0.25 M, double coupling)(Coin et al., 2007). A TentaGel-S-Ram resin was used as solid support. ClAcOH was coupled to the free terminal amino group in fivefold excess together with 5 equivalents (eq.) N,N-diisopropylcarbodiimide (DIC) and 5 eq. 1-hydroxybenzotriazole (HOBt) in dimethylformamide (DMF) for 2 hr at RT. To incorporate the alkyl halide into internal positions, the original residues were exchanged to Fmoc-Lys(Dde)-OH and the last (N-terminal) amino acid was coupled as Nα-tert-butyloxycarbonyl(Boc)-protected. After complete assembly of the sequence on the resin, 1-(4,4-dimethyl-2,6-dioxycyclohexylidene)ethyl (Dde) was selectively removed with 3% hydrazine (v/v) in DMF (12 × 10 min) and ClAcOH was coupled in fivefold excess as described above. Peptides were cleaved from the resin with trifluoroacetic acid (TFA)/H2O (95/5 v/v, 3 hr) and precipitated in diethyl ether. Preparative RP-HPLC was performed on a C18 column (Jupiter Phenomenex 5 u, 300 Å, 250 × 10.0 mm, 5 µm) operated at 4 mL/min, using a linear gradient of acetonitrile (ACN) in H2O with 0.1% TFA from 20% to 60% in 40 min. Peptides were purified to >95%. Mass spectrometric analysis was performed on a MALDI-Tof MS instrument (Ultraflex III, Bruker). Analytic HPLC was run on each two of the following columns: I Phenomenex Jupiter C12, 4 u, 90 Å, 250 × 4.6 mm, 4 µm; II Agilent VariTide RPC, 200 Å, 250 × 4.6 mm, 6 µm; III Phenomenex Jupiter C18, 5 u, 300 Å, 250 × 4.6 mm, 5 µm; using a linear gradient of ACN in H2O with 0.1% TFA from 20% to 70% in 30 min (columns I and II) or from 20% to 70% in 40 min (columns I and III) at a flow of 0.6 mL/min (columns I and III) or 1.0 mL/min (column II).

Cell culture and transfection

HEK293 or 293T cells were cultured in DMEM supplemented with 10% FBS and 100 U/mL penicillin-streptomycin at 37°C, 95% humidity and 5% CO2. Cells were transfected at 70% confluence using 3 µg polyethylenimine (PEI) max per µg total DNA in lactate buffered saline (20 mM Na-lactate pH 4.0, 150 mM NaCl). The transfection mixture was incubated for 10 min at RT and neutralized with medium before adding it to the cells.

cAMP accumulation assay via luciferase reporter

The day prior to transfection, 6 × 106 HEK293 cells were seeded in 10 cm dishes. Cells were co-transfected with 0.5 µg of plasmid encoding the wild-type CRF1R gene under control of a PGK promoter, 5 µg of the reporter construct (humanized PpyRE9 [Branchini et al., 2010] firefly luciferase gene driven by a cAMP-responsive element and followed by a PEST sequence), and 0.5 µg of plasmid encoding Renilla luciferase driven by a CMV promoter. Transfection was performed using PEI max as described above. The following day, cells were trypsinized and transferred into a 96-well plate at a density of 180,000 cells per well. 24 hr later, cells were stimulated for 3 hr at 37°C by adding serial dilutions of the ligand. Each concentration was tested in three wells. Antagonists were applied 20 min prior to agonists. After stimulation, cells were washed with ice-cold HDB (12.5 mM Hepes pH 7.4, 140 nM NaCl, 5 mM KCl) and lysed on the plate in 50 µL of luciferase buffer (10 mM MgSO4, 25 mM glycylclycine, 4 mM EGTA, pH 7.8) supplemented with 1% Triton X-100 and 1 mM dithiothreitol (DTT) for 30 min on ice. The luciferase assay was performed using a BMG LABTECH Omega luminometer equipped with two injectors. 50 µL of luciferin substrate buffer (luciferase buffer supplemented with 0.3 mM luciferin, 1 mM ATP, 1 mM DTT, pH 7.8) were subsequently added to each well and the total luminescence was collected for 2 s after a 3.3 s delay. Afterwards, 50 µL of a 5 µM solution of coelenterazine in HDB were added on each well (1.67 µM final concentration of coelenterazine). The luminescence of Renilla was collected through a 475–30 nm emission filter for 2 s after a 3.8 s delay. Firefly luminescence was normalized for the Renilla luminescence. Curves were fitted by non-linear regression assuming one-site binding using Prism 5.03 for Windows (Graphpad Software Inc., San Diego, CA). EC50 values or the percentages of receptor activation were obtained as mean ± s.e.m from at least three independent experiments, each performed in triplicate.

Photo-crosslinking

Azi was incorporated into CRF1R using established two-plasmid transfection protocols for non-canonical amino acid mutagenesis (Serfling and Coin, 2016), with one plasmid encoding for the CRF1R bearing an amber stop codon TAG at the position designated for mutation and the other plasmid encoding the orthogonal tRNA/amino-acyl tRNA synthetase (aaRS) pair dedicated to Azi. The systematic library of CRF1R-TAG mutants has been described previously (Coin et al., 2013). The plasmid encoding the translational pair contains four tandem copies of the suppressor tRNA Bst-Yam driven by the human U6 promoter and one copy of a humanized gene for the enhanced variant of the Azi-tRNA synthetase (EAziRS) driven by a PGK promoter. The humanized EAziRS gene was synthesized by Invitrogen GeneArt Gene Synthesis (Germany)/ThermoFisher Scientific (Waltham, MA).

0.5 × 106 293T cells per well were seeded in six-well plates. The following day, 0.5 mM Azi were added to the culture medium from a fresh 1000x stock in 0.5 M NaOH 1–2 hr prior to transfection. Cells were co-transfected with 0.5 µg of the CMV-CRF1R-FLAG TAG-mutant plasmid and 0.5 µg of the EAziRS/Bst-Yam plasmid. 48 hr after transfection, the medium was replaced by 800 µL of 100 nM peptide ligand in binding buffer (5 mM MgCl2, 0.1% BSA, 0.01% Triton X-100 in HDB). The samples were incubated for 10 min at RT, followed by crosslinking on ice at 365 nm for 20 min using a BLX-365 crosslinker operated at maximal power (BioBudget Technologies, 5 × 8 Watt tubes). Cell were detached, transferred to 1.5-mL tubes and pelleted at 800 × g. Pellets were resuspended in 40 µL of HDB supplemented with 1x protease inhibitor. The cells were flash-frozen in liquid N2, briefly thawed at 37°C, vortexed and centrifuged at 2500 × g and 4°C for 10 min. The pellets were lysed in Triton lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 1 mM DTT, 1x protease inhibitor) for 30 min on ice. Insoluble debris was separated at 13,000 × g and 4°C for 10 min. The supernatants were prepared for SDS-PAGE by deglycosylation using PNGase F following the supplier’s instructions.

Whole-cell ELISA

A human influenza hemagglutinin (HA) epitope was added between the endogenous cleavable signal peptide (Met1-Thr23) of CRF1R and the receptor using standard cloning methods. All mutants were cloned into pcDNA3.1.

15,000 293T cells were seeded per well of a Poly-D-lysine-coated 96-well plate. The following day, 0.5 mM Azi were added to the culture medium from a fresh 1000x stock in 0.5 M NaOH 1–2 hr prior to transfection. Cells were co-transfected with 5 ng of either HA-CRF1Rwt-FLAG or the HA-CRF1R(xxxTAG)-FLAG mutant plasmid and 5 ng of the EAziRS/Bst-Yam plasmid. The total DNA amount was filled to 100 ng per well with empty pcDNA3 vector. After 24 hr, the medium was removed and cells were fixed in 4% formaldehyde/PBS for 10 min at RT. The formaldehyde was removed by washing 3 × 5 min in PBS. Blocking was performed with DMEM containing 10% FBS for 1 hr at 37°C, followed by the incubation in HRP-conjugated rat-anti-HA-antibodies (Roche, clone 3F10) diluted 1:200 in DMEM containing 10% FBS for 1 hr at 37°C. Unbound antibodies were removed by washing 3 × 5 min in PBS. The read-out was generated by adding a freshly prepared solution of 0.7 mg/mL o-phenylenediamine dihydrochloride (OPD) and 0.08% H2O2 in 50 mM citrate-phosphate buffer. After 30 min at RT in the dark, the reaction was stopped by adding HCl to a final concentration of 170 mM and the absorption at 492 nm (OD492) was measured. The raw data were collected as mean ± s.e.m. from three independent experiments, each performed in triplicates, and corrected for the absorption obtained from mock-transfected cells. The optimal amounts of transfected DNA and the dilution of the antibody were established through a series of preliminary experiments in which we transfected increasing amounts of CRF1Rwt plasmid (0.25–25 ng/well) and analyzed the trends of OD492 signal obtained with variable antibody dilutions (1/100-1/5000).

Pair-wise chemical crosslinking

1.4 × 106 293T cells were seeded in 6-cm dishes the day prior to transfection. Cells were transfected with 0.4 µg of the CMV-CRF1R-FLAG Cys-mutant plasmid filled up to 2 µg total DNA using an empty pcDNA3 vector. 48 hr after transfection, the cells were detached and split into up to six portions. Cells were pelleted at 800 g and resuspended in 100 µL of 100 nM peptide ligand in binding buffer (HDB, 5 mM MgCl2, 0.1% BSA, 0.01% Triton X-100). The samples were incubated for 30 min at RT, detached and pelleted at 800 × g. Pellets were resuspended in 40 µL of HDB supplemented with 1x protease inhibitor cocktail (Roche). The cells were flash-frozen in liquid N2, thawed at 37°C and centrifuged at 2500 × g and 4°C for 10 min. The pellets were lysed in Triton lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 1 mM DTT, 1x protease inhibitor) followed by a 30-min incubation on ice. Insoluble debris was separated at 13,000 × g and 4°C for 10 min. The supernatants were prepared for SDS-PAGE by incubating them for 30 min at 37°C in sample buffer (15 mM Tris-HCl pH 6.8, 0.5% SDS, 2.5% glycerol, 0.01% bromphenolblue, 150 mM DTT).

SDS-PAGE and Western blot

Lysates were resolved on 10% polyacrylamide SDS-gels (Tris-Glycine buffered) and transferred to a PVDF membrane (Millipore Immobilon). Membranes were blocked in 5% non-fat dry milk in TBS-T (20 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 0.1% Tween 20) for 1 hr at RT. The primary antibodies, either rabbit-anti-Ucn1 (PBL #5779) or rabbit-anti-CRF (PBL #rC69) were applied overnight at 4°C (1:5000 in blocking solution), followed by 3 × 10 min wash with TBS-T. The secondary antibodies, either goat-anti-rabbit IgG-HRP (SantaCruz #sc-2004) or mouse-anti-FLAG M2-HRP conjugate (Sigma #A8592) were applied for 1 hr at RT (1:15,000 or 1:5000 in blocking solution, respectively), followed by 3 × 10 min washes in TBS-T. Membranes were soaked in homemade ECL reagent (0.1 M Tris-HCl pH 8.6, 22% luminol, 10% p-coumaric acid, 10% DMSO, 0.0001% H2O2). After 1 min delay, signals were collected for 5 min in the dark (Gbox, Syngene). All Western blot results were replicated at least once with cell lysates from a second individual experiment.

Molecular modeling

Full-length conformational models of CRF-CRF1R and dFXCRF(12-41)-CRF1R complexes were generated with ICM-Pro molecular modeling software (www.molsoft.com) using energy-based restrained conformational modeling algorithm, similar to the procedure described in Coin et al. (2013). The initial models were based on the crystal structures of the human CRF1R domains, the ECD (PDB: 3EHU)(Pioszak et al., 2008) and of the thermostabilized TMD (PDB: 4K5Y)(Hollenstein et al., 2013). Flexibility in the receptor was introduced on two levels during optimization based on the ICM Monte Carlo minimization procedure (Abagyan and Totrov, 1994). The whole receptor was considered flexible in the minimization runs, while extensive Monte Carlo conformational sampling was performed only for side chains located 5 Å from the peptides and specific regions of protein backbone that included the hinge region, ECL3, as well as G3456.50 and G3567.50 ‘backbone hinges’ in helices VI and VII, respectively. Flexible peptide docking and conformational sampling of the complexes was guided by experimentally derived pair-wise crosslinking restraints, which were implemented as soft harmonic potentials between the Cβ of the corresponding residues with zero penalty when restraint is under 10 Å length and harmonic increase in penalty for lengths exceeding 10 Å. An exception was the dF12 residue of dFXCRF(12-41), in which softs harmonic tethers were implemented between the Nα of dF12 and the Cβ of the corresponding residues with the penalty length of 5 Å. The restraint length was derived from the geometry of the reaction product as shown in Figure 4. Global energy optimizations of CRF-CRF1R and dFXCRF(12-41)-CRF1R complexes in internal coordinates were performed by extensive conformational sampling with more than 107 Monte Carlo steps. The final optimization of CRF-CRF1R and dFXCRF(12-41)-CRF1R complexes was done with a fully flexible peptide and receptor without any distance restraints.

Additionally, we generated a full-length conformational model of the active-like CRF-CRF1R complex with incorporated conformational changes in the intracellular side of the receptor, as observed in the recently published structure of the active state complex of the calcitonin receptor with Gs heterotrimer (PDB: 5UZ7) (Liang et al., 2017). This model is based on the CRF-CRF1R complex, as described above, and introduces an outward shift of the intracellular part of the helix VI, mimicking the intracellular conformation of the active state calcitonin receptor structure.

Molecular dynamics simulations

Membrane Builder module of CHARMM-GUI (Lee et al., 2016) server was employed to create homogenous membrane-embedded (POPC) peptide-receptor complexes within a water box, starting from the optimized peptide-receptor complex models obtained with crosslinking-restrained conformational modeling, and the system was suitably ionized to 0.15 M concentration of NaCl. Peptide-receptor complexes were pre-aligned in the OPM (Orientation of Proteins in Membranes) database (Lomize et al., 2006). CRF-CRF1R and dFXCRF(12-41)-CRF1R systems of 163467 and 165848 atoms, respectively, were created, which includes 38381 TIP3 waters and 312 POPC lipids for the CRF-CRF1R system, and 38867 TIP3 waters and 320 POPC lipids for the dFXCRF(12-41)-CRF1R system. Receptor, peptides, lipids, water molecules and ions were modeled according to CHARMM36 force field parameter set (Best et al., 2012). The 12 MD simulations were run, six for CRF-CRF1R and six for dFXCRF(12-41)-CRF1R systems, under Gromacs5.0.4 (Hess et al., 2008) at 310 K temperature with a step size of 2 fs using six GPU-enabled nodes with 16 processors each for a period of 1 µs. Hydrogen atoms were constrained using LINCS and a cut-off of 12 Å was used for Van der Waals and short range electrostatic interactions, along with PME conditions. After minimization and equilibrations, each system was run under distance restraints between peptide and receptor, 7 restraints in case of CRF and 15 in case of dFXCRF(12-41), for an initial period of 20 ns, and switched off afterwards. Distance restraints used harmonic penalty to the potential with 10 factor weight if distances between the pair of atoms exceeded the specified maximum value. All the distance restraints were restrained to a maximum value of 10 Å except the distance restraints between F12 of dFXCRF(12-41) and the receptor, which were restrained to the maximum distance of 5 Å. Following the initial 20 ns of the distance restrained MD run, the distance restraints were switched off in Run2 and Run3 in both CRF-CRF1R and dFXCRF(12-41)-CRF1R systems, to monitor evolution of the peptide-receptor complex in the absence of distance restraints. All the analyses were performed using Gromacs5.0.4 and VMD1.9.2.

Acknowledgements

This research was supported by the Emmy-Noether Program of the Deutsche Forschungsgemeinschaft (DFG) under grant CO822/2-1 to IC, the Netherlands Organization for Scientific Research (NWO) under Rubicon grant 019.161LW.035 to BZ, and by National Institute of Health grant U54 GM094618 to VK. We thank Lei Wang (UCSF) for sharing the library of CRF1R-TAG mutants previously prepared by IC and Tingting Sun at The Salk Institute for Biological Studies, Paul Sawchenko (Peptide Biology Laboratory, The Salk Institute) for sharing the anti-CRF and anti-Ucn1 antibodies prepared by Joan Vaughan, Bruce Branchini (Connecticut College) for sharing the PpyRE9 luciferase gene. We thank Torsten Schöneberg (University of Leipzig) for his help with the ELISA, and Angela Walker for help with preparing the manuscript. The molecular dynamics simulations described in this paper were conducted on the University of Southern California’s Center for High-Performance Computing clusters (hpcc.usc.edu).

Funding Statement

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Funding Information

This paper was supported by the following grants:

  • http://dx.doi.org/10.13039/501100001659Deutsche Forschungsgemeinschaft CO822/2-1 to Lisa Seidel, Irene Coin.
  • http://dx.doi.org/10.13039/100000057National Institute of General Medical Sciences U54 GM094618 to Barbara Zarzycka, Saheem A Zaidi, Vsevolod Katritch.
  • Netherlands Association for Scientific Research 019.161LW.035 to Barbara Zarzycka.

Additional information

Competing interests

The authors declare that no competing interests exist.

Author contributions

LS, Synthesized all peptides, designed and performed all photo- and pair-wise crosslinking experiments, performed the cAMP assays and ELISA, analysed the results, and wrote the manuscript with the contribution of BZ and SZ.

BZ, Performed molecular modelling, analysed the results, and contributed to the manuscript.

SAZ, Performed dynamics simulations, analysed the results, and contributed to the manuscript.

VK, Funding acquisition, Conceived and supervised the computational part of the project, and revised the manuscript.

IC, Funding acquisition, Conceived the project, supervised the biochemistry experiments, and revised the manuscript.

Additional files

10.7554/eLife.27711.022

Supplementary file 1.

Model with bound agonist.

DOI: http://dx.doi.org/10.7554/eLife.27711.022

10.7554/eLife.27711.023

Supplementary file 2.

Model with bound antagonist.

DOI: http://dx.doi.org/10.7554/eLife.27711.023

References

  • Abagyan R, Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. Journal of Molecular Biology. 1994;235:983–1002. doi: 10.1006/jmbi.1994.1052. [PubMed] [Cross Ref]
  • Assil-Kishawi I, Abou-Samra AB. Sauvagine cross-links to the second extracellular loop of the corticotropin-releasing factor type 1 receptor. Journal of Biological Chemistry. 2002;277:32558–32561. doi: 10.1074/jbc.M204964200. [PubMed] [Cross Ref]
  • Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annual Review of Pharmacology and Toxicology. 2004;44:525–557. doi: 10.1146/annurev.pharmtox.44.101802.121410. [PubMed] [Cross Ref]
  • Best RB, Zhu X, Shim J, Lopes PE, Mittal J, Feig M, Mackerell AD. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone [var phi], ψ and side-chain χ(1) and χ(2) dihedral angles. Journal of Chemical Theory and Computation. 2012;8:3257–3273. doi: 10.1021/ct300400x. [PMC free article] [PubMed] [Cross Ref]
  • Beyermann M, Rothemund S, Heinrich N, Fechner K, Furkert J, Dathe M, Winter R, Krause E, Bienert M. A role for a helical connector between two receptor binding sites of a long-chain peptide hormone. Journal of Biological Chemistry. 2000;275:5702–5709. doi: 10.1074/jbc.275.8.5702. [PubMed] [Cross Ref]
  • Bortolato A, Doré AS, Hollenstein K, Tehan BG, Mason JS, Marshall FH. Structure of class B GPCRs: new horizons for drug discovery. British Journal of Pharmacology. 2014;171:3132–3145. doi: 10.1111/bph.12689. [PMC free article] [PubMed] [Cross Ref]
  • Branchini BR, Ablamsky DM, Davis AL, Southworth TL, Butler B, Fan F, Jathoul AP, Pule MA. Red-emitting luciferases for bioluminescence reporter and imaging applications. Analytical Biochemistry. 2010;396:290–297. doi: 10.1016/j.ab.2009.09.009. [PubMed] [Cross Ref]
  • Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nature Protocols. 2007;2:3247–3256. doi: 10.1038/nprot.2007.454. [PubMed] [Cross Ref]
  • Coin I, Perrin MH, Vale WW, Wang L. Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison. Angewandte Chemie International Edition. 2011;50:8077–8081. doi: 10.1002/anie.201102646. [PMC free article] [PubMed] [Cross Ref]
  • Coin I, Katritch V, Sun T, Xiang Z, Siu FY, Beyermann M, Stevens RC, Wang L. Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR. Cell. 2013;155:1258–1269. doi: 10.1016/j.cell.2013.11.008. [PMC free article] [PubMed] [Cross Ref]
  • Cordomi A, Liapakis G, Matsoukas MT. Understanding Corticotropin Releasing Factor receptor (CRFR) Activation Using Structural Models. Current Molecular Pharmacology. 2017;10:1–9. [PubMed]
  • Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Frontiers in Pharmacology. 2015;6:264 doi: 10.3389/fphar.2015.00264. [PMC free article] [PubMed] [Cross Ref]
  • DeVree BT, Mahoney JP, Vélez-Ruiz GA, Rasmussen SG, Kuszak AJ, Edwald E, Fung JJ, Manglik A, Masureel M, Du Y, Matt RA, Pardon E, Steyaert J, Kobilka BK, Sunahara RK. Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature. 2016;535:182–186. doi: 10.1038/nature18324. [PubMed] [Cross Ref]
  • Dong M, Koole C, Wootten D, Sexton PM, Miller LJ. Structural and functional insights into the juxtamembranous amino-terminal tail and extracellular loop regions of class B GPCRs. British Journal of Pharmacology. 2014;171:1085–1101. doi: 10.1111/bph.12293. [PMC free article] [PubMed] [Cross Ref]
  • Dong M, Lam PC, Orry A, Sexton PM, Christopoulos A, Abagyan R, Miller LJ. Use of cysteine trapping to Map Spatial Approximations between residues contributing to the Helix N-capping motif of Secretin and distinct residues within each of the extracellular loops of its receptor. Journal of Biological Chemistry. 2016;291:5172–5184. doi: 10.1074/jbc.M115.706010. [PMC free article] [PubMed] [Cross Ref]
  • Gkountelias K, Tselios T, Venihaki M, Deraos G, Lazaridis I, Rassouli O, Gravanis A, Liapakis G. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. Molecular Pharmacology. 2009;75:793–800. doi: 10.1124/mol.108.052423. [PubMed] [Cross Ref]
  • Grace CR, Perrin MH, Gulyas J, Rivier JE, Vale WW, Riek R. NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. Journal of Biological Chemistry. 2010;285:38580–38589. doi: 10.1074/jbc.M110.121897. [PMC free article] [PubMed] [Cross Ref]
  • Grigoriadis DE, Hoare SR. Non-peptide CRF-Receptor Antagonists: Allosterism, Kinetics and Translation to Efficacy in Human Disease. Current Molecular Pharmacology. 2017;10:1–3. doi: 10.2174/1874467210666170110124539. [PubMed] [Cross Ref]
  • Gulyas J, Rivier C, Perrin M, Koerber SC, Sutton S, Corrigan A, Lahrichi SL, Craig AG, Vale W, Rivier J. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. PNAS. 1995;92:10575–10579. doi: 10.1073/pnas.92.23.10575. [PubMed] [Cross Ref]
  • Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. Journal of Chemical Theory and Computation. 2008;4:435–447. doi: 10.1021/ct700301q. [PubMed] [Cross Ref]
  • Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. Biochemistry. 2004;43:3996–4011. doi: 10.1021/bi036110a. [PubMed] [Cross Ref]
  • Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides. 2005;26:457–470. doi: 10.1016/j.peptides.2004.10.019. [PubMed] [Cross Ref]
  • Hollenstein K, Kean J, Bortolato A, Cheng RK, Doré AS, Jazayeri A, Cooke RM, Weir M, Marshall FH. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature. 2013;499:438–443. doi: 10.1038/nature12357. [PubMed] [Cross Ref]
  • Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC. Insights into the structure of class B GPCRs. Trends in Pharmacological Sciences. 2014;35:12–22. doi: 10.1016/j.tips.2013.11.001. [PMC free article] [PubMed] [Cross Ref]
  • Isberg V, de Graaf C, Bortolato A, Cherezov V, Katritch V, Marshall FH, Mordalski S, Pin JP, Stevens RC, Vriend G, Gloriam DE. Generic GPCR residue numbers - aligning topology maps while minding the gaps. Trends in Pharmacological Sciences. 2015;36:22–31. doi: 10.1016/j.tips.2014.11.001. [PMC free article] [PubMed] [Cross Ref]
  • Jazayeri A, Doré AS, Lamb D, Krishnamurthy H, Southall SM, Baig AH, Bortolato A, Koglin M, Robertson NJ, Errey JC, Andrews SP, Teobald I, Brown AJ, Cooke RM, Weir M, Marshall FH. Extra-helical binding site of a glucagon receptor antagonist. Nature. 2016;533:274–277. doi: 10.1038/nature17414. [PubMed] [Cross Ref]
  • Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in class A GPCR signaling. Trends in Biochemical Sciences. 2014;39:233–244. doi: 10.1016/j.tibs.2014.03.002. [PMC free article] [PubMed] [Cross Ref]
  • Kirkpatrick A, Heo J, Abrol R, Goddard WA. Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor. PNAS. 2012;109:19988–19993. doi: 10.1073/pnas.1218051109. [PubMed] [Cross Ref]
  • Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. Journal of Biological Chemistry. 2012;287:3642–3658. doi: 10.1074/jbc.M111.309328. [PMC free article] [PubMed] [Cross Ref]
  • Kraetke O, Holeran B, Berger H, Escher E, Bienert M, Beyermann M. Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues. Biochemistry. 2005;44:15569–15577. doi: 10.1021/bi0507027. [PubMed] [Cross Ref]
  • Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, Wei S, Buckner J, Jeong JC, Qi Y, Jo S, Pande VS, Case DA, Brooks CL, MacKerell AD, Klauda JB, Im W. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations using the CHARMM36 additive force field. Journal of Chemical Theory and Computation. 2016;12:405–413. doi: 10.1021/acs.jctc.5b00935. [PMC free article] [PubMed] [Cross Ref]
  • Liang YL, Khoshouei M, Radjainia M, Zhang Y, Glukhova A, Tarrasch J, Thal DM, Furness SGB, Christopoulos G, Coudrat T, Danev R, Baumeister W, Miller LJ, Christopoulos A, Kobilka BK, Wootten D, Skiniotis G, Sexton PM. Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. Nature. 2017;546:118–123. doi: 10.1038/nature22327. [PubMed] [Cross Ref]
  • Liapakis G, Venihaki M, Margioris A, Grigoriadis D, Gkountelias K. Members of CRF family and their receptors: from past to future. Current Medicinal Chemistry. 2011;18:2583–2600. doi: 10.2174/092986711795933704. [PubMed] [Cross Ref]
  • Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI. OPM: orientations of proteins in membranes database. Bioinformatics. 2006;22:623–625. doi: 10.1093/bioinformatics/btk023. [PubMed] [Cross Ref]
  • Miller LJ, Chen Q, Lam PC, Pinon DI, Sexton PM, Abagyan R, Dong M. Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. Journal of Biological Chemistry. 2011;286:15895–15907. doi: 10.1074/jbc.M110.217901. [PMC free article] [PubMed] [Cross Ref]
  • Monaghan P, Thomas BE, Woznica I, Wittelsberger A, Mierke DF, Rosenblatt M. Mapping peptide hormone-receptor interactions using a disulfide-trapping approach. Biochemistry. 2008;47:5889–5895. doi: 10.1021/bi800122f. [PMC free article] [PubMed] [Cross Ref]
  • Nygaard R, Zou Y, Dror RO, Mildorf TJ, Arlow DH, Manglik A, Pan AC, Liu CW, Fung JJ, Bokoch MP, Thian FS, Kobilka TS, Shaw DE, Mueller L, Prosser RS, Kobilka BK. The dynamic process of β(2)-adrenergic receptor activation. Cell. 2013;152:532–542. doi: 10.1016/j.cell.2013.01.008. [PMC free article] [PubMed] [Cross Ref]
  • Pal K, Melcher K, Xu HE. Structure and mechanism for recognition of peptide hormones by class B G-protein-coupled receptors. Acta Pharmacologica Sinica. 2012;33:300–311. doi: 10.1038/aps.2011.170. [PMC free article] [PubMed] [Cross Ref]
  • Perry SJ, Junger S, Kohout TA, Hoare SR, Struthers RS, Grigoriadis DE, Maki RA. Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated. Journal of Biological Chemistry. 2005;280:11560–11568. doi: 10.1074/jbc.M412914200. [PubMed] [Cross Ref]
  • Pioszak AA, Parker NR, Suino-Powell K, Xu HE. Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. Journal of Biological Chemistry. 2008;283:32900–32912. doi: 10.1074/jbc.M805749200. [PMC free article] [PubMed] [Cross Ref]
  • Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011;477:549–555. doi: 10.1038/nature10361. [PMC free article] [PubMed] [Cross Ref]
  • Rivier J, Rivier C, Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science. 1984;224:889–891. doi: 10.1126/science.6326264. [PubMed] [Cross Ref]
  • Rivier JE, Rivier CL. Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Frontiers in Neuroendocrinology. 2014;35:161–170. doi: 10.1016/j.yfrne.2013.10.006. [PMC free article] [PubMed] [Cross Ref]
  • Serfling R, Coin I. Incorporation of Unnatural amino acids into proteins expressed in mammalian cells. Methods in Enzymology. 2016;580:89–107. doi: 10.1016/bs.mie.2016.05.003. [PubMed] [Cross Ref]
  • Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, Zhou C, Xu Q, Wacker D, Joseph JS, Liu W, Lau J, Cherezov V, Katritch V, Wang MW, Stevens RC. Structure of the human glucagon class B G-protein-coupled receptor. Nature. 2013;499:444–449. doi: 10.1038/nature12393. [PMC free article] [PubMed] [Cross Ref]
  • Stengel A, Taché Y. CRF and urocortin peptides as modulators of energy balance and feeding behavior during stress. Frontiers in Neuroscience. 2014;8:52 doi: 10.3389/fnins.2014.00052. [PMC free article] [PubMed] [Cross Ref]
  • Wheatley M, Wootten D, Conner MT, Simms J, Kendrick R, Logan RT, Poyner DR, Barwell J. Lifting the lid on GPCRs: the role of extracellular loops. British Journal of Pharmacology. 2012;165:1688–1703. doi: 10.1111/j.1476-5381.2011.01629.x. [PMC free article] [PubMed] [Cross Ref]
  • Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. PNAS. 2013;110:5211–5216. doi: 10.1073/pnas.1221585110. [PubMed] [Cross Ref]
  • Wootten D, Miller LJ, Koole C, Christopoulos A, Sexton PM. Allostery and biased agonism at class B G Protein-Coupled receptors. Chemical Reviews. 2017;117:111–138. doi: 10.1021/acs.chemrev.6b00049. [PubMed] [Cross Ref]
  • Xiang Z, Ren H, Hu YS, Coin I, Wei J, Cang H, Wang L. Adding an unnatural covalent bond to proteins through proximity-enhanced bioreactivity. Nature Methods. 2013;10:885–888. doi: 10.1038/nmeth.2595. [PMC free article] [PubMed] [Cross Ref]
  • Xiang Z, Lacey VK, Ren H, Xu J, Burban DJ, Jennings PA, Wang L. Proximity-enabled protein crosslinking through genetically encoding haloalkane unnatural amino acids. Angewandte Chemie International Edition. 2014;53:2190–2193. doi: 10.1002/anie.201308794. [PMC free article] [PubMed] [Cross Ref]
  • Yang L, Yang D, de Graaf C, Moeller A, West GM, Dharmarajan V, Wang C, Siu FY, Song G, Reedtz-Runge S, Pascal BD, Wu B, Potter CS, Zhou H, Griffin PR, Carragher B, Yang H, Wang MW, Stevens RC, Jiang H. Conformational states of the full-length glucagon receptor. Nature Communications. 2015;6:7859 doi: 10.1038/ncomms8859. [PMC free article] [PubMed] [Cross Ref]
  • Zhang H, Qiao A, Yang D, Yang L, Dai A, de Graaf C, Reedtz-Runge S, Dharmarajan V, Zhang H, Han GW, Grant TD, Sierra RG, Weierstall U, Nelson G, Liu W, Wu Y, Ma L, Cai X, Lin G, Wu X, Geng Z, Dong Y, Song G, Griffin PR, Lau J, Cherezov V, Yang H, Hanson MA, Stevens RC, Zhao Q, Jiang H, Wang MW, Wu B. Structure of the full-length glucagon class B G-protein-coupled receptor. Nature. 2017;546:259–264. doi: 10.1038/nature22363. [PMC free article] [PubMed] [Cross Ref]
2017; 6: e27711.

Decision letter

Yibing Shan, Reviewing editor
Yibing Shan, DE Shaw Research, United States;

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article "Activation of a Class B GPCR by peptide hormones: structural insight from live cells" for consideration by eLife. Your article has been favorably evaluated by Richard Aldrich (Senior Editor) and three reviewers, one of whom, Yibing Shan (Reviewer #1), is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal his identity:.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Aiming to elucidate the structural changes associated with activation of Class-B GPCRs, this work used molecular dynamics simulations guided by extensive crosslinking data to construct structural models of corticotropin-releasing factor receptor type 1 (CRF1R) bound with an agonist or with an antagonist. The models suggest a conserved hinge motion and helix tilting in the vicinity of the ligand binding site.

Essential revisions:

MD simulations showed that the "compact" TMD conformation is more optimal than the "wide" conformation for CRF1R interactions with the antagonist. Movements of the extracellular parts of helices VI and VII accounts for the different conformational changes of TMD and may be a key feature of class B GPCR activation. Thus, MD simulation is critical to draw the activation mechanism of class B GPCR by peptide hormones. But the time-scale of nine MD simulations for different systems are inconsistent (Figure 7). As receptors are flexible without distance restraints, in the revision the authors should consider extend run2 and run3 to at least 1-us to provide more convincing results.

The reviewers notice that the agonist and the antagonist models are virtually identical at the cytoplasmic side. This is unlikely to be correct because conformational change at and near the ligand binding site has to be propagated to cytoplasmic side to pass the signal to downstream G proteins. Likely this is due to the simulations' failure in reaching a global equilibrium. In the revision, the models should be adaquated "relaxed" by unrestrained simulations. Other means such as slow mode analysis or coarse-grained simulation may also be appropriate to address this concern. The conformational difference in the cytoplasmic side should be clarified and discussed in the functional context.

Essential revisions:

MD simulations showed that the "compact" TMD conformation is more optimal than the "wide" conformation for CRF1R interactions with the antagonist. Movements of the extracellular parts of helices VI and VII accounts for the different conformational changes of TMD and may be a key feature of class B GPCR activation. Thus, MD simulation is critical to draw the activation mechanism of class B GPCR by peptide hormones. But the time-scale of nine MD simulations for different systems are inconsistent (Figure 7). As receptors are flexible without distance restraints, in the revision the authors should consider extend run2 and run3 to at least 1-us to provide more convincing results.

We have extended all the MD simulations in this work to 1 us for consistency, see Figure 7, ,8,8, ,99 and Figure 7—figure supplement 1.

The reviewers notice that the agonist and the antagonist models are virtually identical at the cytoplasmic side. This is unlikely to be correct because conformational change at and near the ligand binding site has to be propagated to cytoplasmic side to pass the signal to downstream G proteins. Likely this is due to the simulations' failure in reaching a global equilibrium. In the revision, the models should be adaquated "relaxed" by unrestrained simulations. Other means such as slow mode analysis or coarse-grained simulation may also be appropriate to address this concern. The conformational difference in the cytoplasmic side should be clarified and discussed in the functional context.

We agree with the reviewers that the intracellular side of our agonist‐bound receptor model does not reflect all the conformational changes in the active‐like receptors. While our model focuses on accurate presentation of changes in the ligand‐receptor interactions driven by experimental crosslinking data, the lack of intracellular restrains prevented accurate modeling in this part of the receptor. Moreover, the changes we observed in the intracellular side in 1us MD simulations were minor, suggesting that proper activation‐related helical rearrangement require much longer time scales as observed previously in class A receptors.

Fortunately, the very recently published electron microscopy structure of calcitonin receptor in active‐state Gs‐bound form (PDB: 5UZ7) (Liang et al., 2017) now provides a reasonable template for modeling of the intracellular rearrangements in the class B receptors. The structure shows dramatic kink and the outward bend in the helix VI around G6.50 flexible hinge, fully conserved in class B GPCRs. To analyze the active‐like changes in the intracellular part of CRF1R, we modified the CRF1RCRF model with a similar outward bend of helix VI in the intracellular side as observed in the calcitonin receptor structure. The modified model was subjected to unrestrained MD simulations, demonstrating its stability and persistence of the helix VI outward bend. Conservation of G6.50 in class B suggests that this mechanism of outward bend of both extracellular and intracellular parts of helix VI can be common for class B GPCRs. We implemented corresponding changes in Results and Discussion sections, and added Figure 8 to illustrate these new findings. We have also updated the Introduction to include the most recent structural data.


Articles from eLife are provided here courtesy of eLife Sciences Publications, Ltd